Informatics & Analytics

September 12, 2018

The Future of BioManufacturing: Automated Closed Systems for Cell & Gene Therapy Processes

August 10, 2018
Democratising DNA: 23andMe & GSK Collaboration Raises Privacy & Data Quality Concerns - Can Blockchain Offer a Disruptive Solution?

Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?

[vc_row][vc_column][vc_column_text] Personal genomics company 23andMe recently entered a four-year $500M collaborative agreement with major pharmaceutical company GlaxoSmithKline. The deal gives GSK access to the genetic data […]
June 4, 2018

The Future of BioManufacturing: In Silico Modelling

March 27, 2018

All Eyes on Oxford Nanopore after further £100m funding raised at £1.5B Valuation

[vc_row][vc_column][vc_column_text] Oxford Nanopore recently announced that it has attracted a further £100M in funding. The latest investment round values Oxford Nanopore at £1.5B, with Singapore-based GIC, […]
January 30, 2018
GLOBAL DRUG DEVELOPMENT IPOs: $6.4B Raised as Bullish Investors Back Biologics & Gene Therapies Despite Slowed Growth in 2017

Global Therapeutic IPO Review: $6.4B Raised as Bullish Investors Back Biologics & Gene Therapies Despite Slowed Growth in 2017

[vc_row][vc_column][vc_column_text]2017 saw a total of 73 Drug Development IPOs across 15 global exchanges, compared to 58 IPOs in 2016. In total approximately $6.4B was raised, 1% […]
January 23, 2018
Gene Therapy Manufacturing: An Impending Crisis or Temporary Growing Pains?

Gene Therapy Manufacturing: An Impending Crisis or Temporary Growing Pains?

[vc_row][vc_column][vc_column_text]The Food and Drug Administration recently announced the first ever approval of a directly administered gene therapy in the United States. Spark Therapeutics one-time gene therapy […]
December 8, 2017

The Future of BioManufacturing: Downstream Processing

October 24, 2017
Monogenic Gene Therapies: Will Spark Therapeutics’ Luxturna Avoid the Fate of Glybera & Strimvelis?

Monogenic Gene Therapies: Will Spark Therapeutics’ Luxturna Avoid the Fate of Glybera & Strimvelis?

[vc_row][vc_column][vc_column_text] Philadelphia-based Spark Therapeutics recently received unanimous backing from an FDA advisory panel for Luxturna™, a one-shot gene therapy treatment for biallelic RPE65-mediated inherited retinal dystrophy […]
October 5, 2017
Slow Quarter for the Global Therapeutic IPO Market: 13 Companies Raise Over $1B in Q3 2017

2017 Global Therapeutic IPO Market: 121% YOY Increase in Funds Raised Despite Slow Q3

[vc_row][vc_column][vc_column_text] The global therapeutic IPO market has failed to maintain the upward momentum established throughout a busy Q2 2017, with just over $1B raised by 13 […]
Contact Us